News and Trends 16 Nov 2016 New Private Placement to Boost the Profitable Therapeutic Antibody Market MorphoSys has announced a private placement of shares to raise funds for its antibody therapy programs. With this push, the company is solidifying its position as a leader in the… November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2019 Sanofi Obtains License for French Company’s Antibody Engineering Platform …a trend of big pharma companies paying for multi-specific antibody technology from smaller partners. Last year, Takeda and the US company Denali Therapeutics began using bispecific antibody technology from UK-based… January 15, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Nov 2017 German Biotech Teams Up with BioNTech to Boost Antibody Development MAB Discovery and BioNTech are working together to push through the development of new antibody therapeutics using MAB’s technology platform. MAB Discovery creates monoclonal antibodies by stimulating natural antibody maturation… November 6, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Feb 2018 Money, Money, Money! Europe’s Best-Funded Biotechs in 2018 …core focus is the discovery and development of new antibody-based drugs for the treatment of cancer, immune disorders, and inflammatory diseases. Novimmune’s innovation lies in their monoclonal and bispecific antibody… February 20, 2018 - 11 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email
In Depth 30 Apr 2025 The future of NSCLC treatment: what’s in store for the therapeutic space? …AstraZeneca is also developing datopotamab deruxtecan, which is an antibody-drug conjugate (ADC) for locally advanced NSCLC. ADCs are composed of a monoclonal antibody that fits into tumor antigens when binding… April 30, 2025 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2022 New COVID antibody cocktail developed …in live virus neutralization assays. The cocktail and each antibody also outperformed other monoclonal treatments currently approved or authorized by the FDA and EMA, particularly against Omicron. “Antibody cocktails will… June 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2019 ViiV Healthcare Licenses Long-Acting Antibody to Attack Hidden HIV …of Health, US. ViiV Healthcare’s majority shareholder, the pharma company GSK, licensed the antibody from the US organization, and ViiV Healthcare will launch a phase IIa trial of the antibody… November 22, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 30 Nov 2017 Cha-Ching! Danish Biotech Gets $5M as Antibody-Antibiotic Combo Enters Phase Ib A Phase Ib trial will assess the capacity of Symphogen’s antibody to direct an antibiotic to Staphylococcus infections for their effective treatment. Symphogen focuses on the development of antibodies for… November 30, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 7 May 2025 Top biotech deals of April 2025 …company will be centered on. Furthermore, U.K.-based Epsilogen’s takeover of Massachusetts-based TigaTx will combine IgA antibody assets to pioneer new antibody therapeutics to address cancer. The acquisition is bound to… May 7, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2017 In the Age of Biological Therapeutics, Chemists move to ADCs …ADCs include the absence of data on unconjugated antibody testing, criteria for an acceptable amount of unconjugated antibody, and data relating to the drug-antibody ratio. Images from the author … February 23, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 20 Sep 2017 New UK Team will develop Next-Generation Antibody-Drug Conjugates for Cancer Glythera and IONTAS have partnered to develop next-generation antibody-drug conjugates that are less toxic and more potent against difficult-to-treat tumors. Glythera has teamed up with antibody developer IONTAS to work… September 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 7 Nov 2025 Top biotech deals in October 2025 …As a result, Novartis will take the reins of the latter’s Antibody Oligonucleotide Conjugates (AOCs) platform from which its clinical candidate for Duchenne muscular dystrophy – a genetic disorder characterized by the progressive loss of… November 7, 2025 - 13 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email